评估药剂师的知识和实践,涉及饮食补充剂omega-3脂肪酸
James M Backes1, Craig J Beavers2, Dave L Dixon3
1Associate Dean for Clinical and Medical Center Affairs, University of Kansas Medical Center, KU School of Pharmacy, Lawrence, Kansas, USA (Dr Backes).
Journal of clinical lipidology
|October 10, 2025
概括
药剂师表现出有关omega-3脂肪酸食补充剂 (OM3FA-DS) 的各种知识和实践. 尽管质量问题和缺乏指导方针,但许多人建议OM3FA-DS,强调需要更好的教育.
科学领域:
- 药理学 药理学是指药理学的学科.
- 营养科学 营养科学
- 药房实践 在药房实践.
背景情况:
- 欧米茄-3脂肪酸食补充剂 (OM3FA-DS) 是广泛使用的.
- 药剂师在为患者提供补充剂使用建议方面发挥着关键作用.
- 医疗保健专业人员之间存在关于OM3FA-DS的知识差距和实践差异.
研究的目的:
- 评估许可药剂师关于OM3FA-DS. 的知识和临床实践.
- 确定与OM3FA-DS.相关的共同建议,咨询实践和问题.
主要方法:
- 一项在线调查分发给经营许可的药剂师.
- 参与者包括国家药房协会和专业网络的成员.
- 分析了583项完成调查的数据.
主要成果:
- 64%的药剂师推OM3FA-DS,主要用于心脏健康和甘油三.
- 对产品质量 (95%),标签和成分的担忧是普遍存在的.
- 41%的人总是或经常接受关于副作用的咨询;出血和药物相互作用引起了关注.
结论:
- 药剂师对OM3FA-DS的建议和咨询存在显著的变化.
- 尽管质量问题和指南支持有限,但大多数人建议OM3FA-DS.
- 药剂师强烈希望改善关于食补充剂的教育和资源,特别是OM3FA-DS.
相关概念视频
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
204
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
204
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Factors Influencing Drug Absorption: Pharmaceutical Parameters
402
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
402
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232


